29 studies found for:    Open Studies | "Gout"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Gout"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Gout: Allopurinol vs. Febuxostat
Conditions: Gout;   Chronic Kidney Diseases
Interventions: Drug: Allopurinol;   Drug: Febuxostat;   Drug: Placebo, vehicle control (Febuxostat-shaped);   Drug: Placebo, vehicle control (Allopurinol-shaped)
2 Unknown  Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
Conditions: Hyperuricemia;   Gout
Intervention: Drug: levotofisopam
3 Recruiting Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study
Conditions: Gout;   Chronic Kidney Diseases
Interventions: Drug: Anakinra 100mg and Placebo Depo-Medrone;   Drug: Depo-Medrone 120mg and Placebo (Anakinra)
4 Not yet recruiting SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO 2 Study
Conditions: Gout;   Low Medication Adherence;   Health Related Quality of Life
Intervention: Behavioral: Improvement of Medication Adherence
5 Recruiting Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen
6 Not yet recruiting Study of URC102 to Assess the Safety and Efficacy in Gout Patients
Conditions: Gout;   Hyperuricemia
Interventions: Drug: URC102;   Drug: Placebo
7 Recruiting Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
Conditions: Gout;   Hyperuricemia
Interventions: Drug: URC102 0.25mg;   Drug: URC102 0.5mg;   Drug: URC102 1.0mg;   Drug: URC102 2.0mg;   Drug: placebo
8 Unknown  The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
Conditions: Antiphospholipid Syndrome;   Endothelial Dysfunction;   Hyperuricemia;   Gout;   Metabolic Syndrome
Intervention:
9 Recruiting Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
Condition: Gout
Interventions: Drug: Bucillamine;   Drug: Colchicine
10 Recruiting Intensive Urate Lowering Therapy With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout
Condition: Gout
Interventions: Drug: Febuxostat 80/120mg/day;   Drug: Allopurinol 100 up to 600mg/day;   Drug: Colchicine;   Drug: Naproxen;   Drug: Omeprazole
11 Recruiting Observational Study of the Use of KRYSTEXXA® in Refractory Chronic Gout
Condition: Chronic Gout
Intervention: Biological: pegloticase
12 Recruiting A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: AC-201;   Drug: Febuxostat
13 Recruiting Elastography as Gouty Arthropathy Outcome (EGO)
Condition: Gout
Intervention:
14 Recruiting Genetics of Hyperuricemia Therapy in Hmong
Condition: Hyperuricemia, Gout
Intervention: Drug: Allopurinol
15 Recruiting Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Condition: Gout
Intervention: Biological: Pegloticase
16 Recruiting Rheumatology Informatics System for Effectiveness
Conditions: Rheumatoid Arthritis;   Osteoarthritis;   Gout
Intervention:
17 Unknown  Impact of Unapproved Drug Initiative on Colchicine Use
Condition: Gout
Intervention:
18 Recruiting Purine Metabolism Enzyme SNP to Uric Acid Production
Conditions: Gout;   Hyperuricemia
Intervention:
19 Recruiting Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
Condition: Gout
Interventions: Drug: SEL-110;   Biological: SEL-212;   Biological: SEL-037
20 Not yet recruiting RDEA3170 PK/PD Study
Condition: Gout
Interventions: Drug: RDEA3170 4.5 mg;   Drug: RDEA3170 6 mg;   Drug: RDEA3170 12 mg

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Indicates status has not been verified in more than two years